Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PTX 100

Next Previous
Search
Drug Profile

PTX 100

Alternative Names: GGTI-2418; PTX-100

Latest Information Update: 21 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator H. Lee Moffitt Cancer Center and Research Institute; University of South Florida; Yale University
  • Developer Prescient Therapeutics
  • Class Amides; Antineoplastics; Imidazoles; Pentanoic acids; Peptidomimetics; Piperazines; Small molecules
  • Mechanism of Action Geranylgeranyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer; Solid tumours

Most Recent Events

  • 01 Mar 2025 Prescient Therapeutics plans a phase II trial for Cutaneous-T cell lymphoma (Second-line therapy or greater, Monotherapy) in USA, Australia, France, Italy (IV, Infusion) in March 2025 (NCT06854653)
  • 09 Dec 2023 Safety, efficacy and pharmacodynamics data from a Phase-I clinical trial in Cancer presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
  • 28 Oct 2022 No recent reports of development identified for phase-I development in Cancer(Late-stage disease) in Australia (IV, Infusion)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top